Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis

What this study is about

This study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers). Two (2) out of three (3) participants will receive active product. The participants will have four (4) visits over eight (8) weeks. Physical exams and photos will be performed. A variety of questions will be asked describing level of pain and lifestyle changes.

Who can join (things the study team will check)

✅ You may be able to join if…

• Diagnosis of systemic sclerosis (scleroderma)
• At least one "active" digital ulcer
• Medication for systemic sclerosis unchanged for 30 days

🚫 You may not be able to join if…

• Infection or gangrene in ulcer
• Citrus allergy
• Unstable heart, kidney, or liver disease
• Active infection of any type
• Current cancer treatment or uncured cancer
• Pregnancy or breast feeding

Where this trial is running

• University of Calgary, Calgary, Alberta, Canada
• Dalhousie University, Halifax, Nova Scotia, Canada
• Saint Joseph Health Care Centre, London, Ontario, Canada
• The Ottawa Hospital, Ottawa, Ontario, Canada
• Mount Sinai Health System, Toronto, Ontario, Canada

Who to contact

Lukban · (480) 483-1410 · jlukban@primusrx.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06256575.